That would be a special case — the same as if the patient had cancer (or one of our many other potential indications). Leronlimab would almost certainty address the HIV with its well-established MOA as an entry inhibitor, and it would likely address the immune deficiency with its other MOA, though the evidence for that is still being gathered.